UniQure (NASDAQ:QURE) has presented 26-week clinical data from the Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec showing ...
https://www.google.com/url?rct=j&sa=t&url=https://seekingalpha.com/news/3695837-uniqures-aav5-gene-therapy-shows-clinical-benefit-in-hemophilia-b-patients-with-pre-existing-nabs&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNGbGxR338cLsmSlfL9JnoEgk1EPpw
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.